Cohn Claudia S, Dunbar Nancy M, Kaplan Alesia, Spinella Philip C, Young Pampee P, Ziman Alyssa
Department of Laboratory Medicine and Pathology, M-Health Fairview, Minneapolis, Minnesota, USA.
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Transfusion. 2025 Jul;65(7):1218-1222. doi: 10.1111/trf.18289. Epub 2025 May 25.
There has been renewed interest in cold-stored platelets (CSPs) for the management of bleeding patients. CSPs might offer advantages over conventional room temperature stored platelet units (RTP), such as a lower risk of bacterial growth during storage, a longer shelf lf life, and possibly improved hemostatic effectiveness. However, CSPs have reduced in vivo survival compared to RTP. In 2023, the FDA issued guidance allowing 14-day storage of CSPs for the treatment of active bleeding when conventional platelets are not available or their use is not practical. This How Do We describes various scenarios of CSP use, followed by the authors' assessment regarding consistency with FDA recommendations.
The authors contributed scenarios that reflected their institutions' unique settings or more generalized scenarios common to other centers. The authors offered their interpretation of the guidance for each specific situation.
Seven scenarios are provided that demonstrate potentially appropriate or clearly inappropriate CSP use across a variety of settings. The authors' interpretations aim to help hospital transfusion services develop standard operating procedures (SOPs) that are suitable for their own unique circumstances.
Each hospital has a unique setting and set of conditions that influence CSP use. This How Do We provides the authors' assessments regarding how CSPs may be used in certain scenarios; however, this is not a guide and does not offer official recommendations. Every center must develop SOPs that account for usage patterns and inventory constraints specific to its own environment.
对于出血患者的管理，冷藏血小板（CSP）重新引起了人们的关注。与传统的室温储存血小板单位（RTP）相比，CSP可能具有优势，例如储存期间细菌生长风险较低、保质期更长，以及可能提高止血效果。然而，与RTP相比，CSP的体内存活率降低。2023年，美国食品药品监督管理局（FDA）发布指南，允许在无法获得传统血小板或使用传统血小板不实际的情况下，将CSP储存14天用于治疗活动性出血。本“我们如何做”描述了CSP使用的各种情况，随后是作者关于与FDA建议一致性的评估。
作者提供了反映其机构独特情况或其他中心常见的更普遍情况的场景。作者对每种具体情况的指南进行了解释。
提供了七个场景，展示了在各种情况下CSP潜在合适或明显不合适的使用情况。作者的解释旨在帮助医院输血服务部门制定适合其自身独特情况的标准操作程序（SOP）。
每家医院都有独特的情况和条件，会影响CSP的使用。本“我们如何做”提供了作者关于CSP在某些情况下如何使用的评估；然而，这不是一份指南，也不提供官方建议。每个中心都必须制定考虑其自身环境特定使用模式和库存限制的SOP。
